To develop monoclonal antibody biomanufacturing innovations and produce an anti-filovirus Medical Countermeasure.
Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback